Phase 2 Study of Decitabine Combined with a JAK Inhibitor as a Treatment Before Stem Cell Transplant in Patients with Advanced Myeloproliferative Neoplasms

What this Trial Is About

Researchers are evaluating a phase II trial studying the effects of decitabine combined with one of three drugs ruxolitinib, fedratinib, or pacritinib, for patients with accelerated or blast phase myeloproliferative neoplasms, a type of tumor affecting blood cell production. These drugs work by stopping tumor cells from growing or spreading. The study aims to see if this combination before a hematopoietic stem cell transplant works better than other treatments or no pre-transplant therapy. Participants receive decitabine intravenously once daily for 10 days, along with either ruxolitinib twice daily, fedratinib once daily, or pacritinib twice daily for 28 days. This treatment cycle repeats every 28 days for up to six cycles unless the disease progresses or side effects become unacceptable. Throughout the trial, blood and bone marrow samples are collected to monitor the patients condition. After treatment, patients are followed for up to five years to track outcomes such as the proportion who receive stem cell transplants, remission rates, survival, relapse-free survival, and genetic changes. The study involves regular assessments, including laboratory tests and questionnaires, to evaluate patient responses and safety. The total participation duration varies with the treatment and follow-up periods.

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms